Administration of P110, a Drp1 blocker, produced neuroprotection in an MPTP-induced mouse model of PD by inhibiting the p53 apoptotic pathway via Drp1-dependent mitochondrial translocation. This evidence concerns the gene DNM1L and Parkinson disease.